ArticleThe Journal of infectious diseases2021
The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Rotavirus vaccine coverage, completion, and compliance: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- Safety and immunogenicity of inactivated human Rotavirus vaccine in young children and infants: a randomized, placebo-controlled, double-blind, phase I clinical trial.Nature communications · 2026Trial
- Trends and burden of diarrhoeal diseases across India, 1990 - 2023: A systematic analysis from the global burden of disease study 2023.New microbes and new infections · 2026Article
- Epidemiology and Clinical Impact of Pediatric Viral Gastroenteritis Before and After Rotavirus Vaccination in Sicily.Pathogens (Basel, Switzerland) · 2026Article
- Rapid development of a robust cultivation process for subunit rotavirus vaccine antigen expression in Escherichia coli with the quality by design approach.Bioprocess and biosystems engineering · 2026Article
- Article
- Viral diarrhea in Ghana: a scoping review of disease burden, epidemiology, and control strategies.Frontiers in public health · 2026Article
- Adverse Effects on Child Health from United States Retrenchment on Global Scientific Collaboration: Examples from Gastroenterology, Hepatology, and Nutrition.The Journal of pediatrics · 2025Article
- A review of childhood rotavirus vaccination policies and a presentation of vaccine coverage trends at national and regional level, Italy, 2016 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Review
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- Article
- Factors associated with antibiotic use in children hospitalized for acute viral gastroenteritis and the relation to rotavirus vaccination.Human vaccines & immunotherapeutics · 2024Article
- Article
- Article
- Article
- Navigating Viral Gastroenteritis: Epidemiological Trends, Pathogen Analysis, and Histopathological Findings.Cureus · 2024Article
- Correlates of immune protection against human rotaviruses: natural infection and vaccination.Archives of virology · 2024Review
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- Review
- No increased risk of intussusception after pentavalent rotavirus vaccination in China: a retrospective birth cohort using electronic health records of Ningbo city.Emerging microbes & infections · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, rotavirus is the leading pathogen causing severe diarrhea in children and a major cause of under 5 years mortality. In 1998, the first rotavirus vaccine, RotaShield, was licensed in the United States but a rare adverse event, intussusception, led to its withdrawal. Seven years passed before the next generation of vaccines became available, Rotarix (GSK) and Rotateq (Merck), and 11 years later, 2 additional vaccines from India, Rotavac (Bharat) and Rotasiil (Serum Institute), were recommended by World Health Organization for all children. Today, these vaccines are used in more than 100 countries and have contributed to marked decreases in hospitalizations and deaths from diarrhea. However, these live oral vaccines are less effective in low-income countries with high under 5 years mortality for reasons that are not understood. Efforts to develop new vaccines that avoid the oral route are in progress and will likely be needed to ultimately control rotavirus disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.